Skip to main
IBIO

iBio (IBIO) Stock Forecast & Price Target

iBio (IBIO) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

iBio is a preclinical biotechnology company that leverages the power of Artificial Intelligence (AI) to develop precision antibodies for hard-to-target cancers and other diseases. The company's AI-guided epitope-steering technology and monoclonal antibody optimization reduce downstream risks, making it an attractive target for investors. However, its development stage and lack of revenue-generating products may require future fundraising, which could dilute stock value. Additionally, the company faces significant competition in the biotechnology and pharmaceutical industries. Despite these challenges, iBio's promising potential and innovative platform make it a compelling investment opportunity for those with a longer time horizon.

Bears say

iBio is a relatively early stage biotechnology company with a preclinical pipeline that has yet to generate any revenue. They face significant competition in the biotech and pharma industries and will likely need to raise additional capital in the future. Additionally, there is no guarantee that their intellectual property will sufficiently protect their product candidates, which could lead to potential legal expenses. All of these factors contribute to a negative outlook on iBio's stock.

iBio (IBIO) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of iBio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About iBio (IBIO) Forecast

Analysts have given iBio (IBIO) a Buy based on their latest research and market trends.

According to 4 analysts, iBio (IBIO) has a Buy consensus rating as of May 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

iBio (IBIO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.